. 2018 Jul 24;32(5):425–440. doi: 10.1007/s40259-018-0295-0

Table 1.

Biologic treatments for subcutaneous administration in rheumatoid arthritis [64, 65]

Molecule	Brand name (originator)	Dosing frequency	Injection volume	Device
Anti-TNFα
Etanercept	Enbrel (Amgen)^a	q1w or twice weekly	0.5–1 ml	Prefilled syringe, vial, prefilled pen/autoinjector, prefilled cartridge for reusable autoinjector
Adalimumab	Humira (AbbVie)^a	q2w	0.4–0.8 ml	Prefilled syringe, vial, prefilled pen
Certolizumab pegol	Cimzia (UCB - Euronext and BEL20)^a	q2w and q4w	1 ml	Prefilled syringe, vial, prefilled pen
Golimumab	Simponi (Janssen)^b	q1m	0.5–1 ml	Prefilled syringe, prefilled pen/autoinjector
Anti-IL-6
Tocilizumab	Actemra (Roche)^b	q1w and q2w	0.9 ml	Prefilled syringe, prefilled pen
Sarilumab	Kevzara (Sanofi-Aventis)^a	q2w	1.14 ml	Prefilled syringe, prefilled pen
Anti-IL-1
Anakinra	Kineret (Swedish Orphan Biovitrum GmbH)^a	q1d or q2d	0.67 ml	Prefilled syringe
Selective co-stimulating modulator
Abatacept	Orencia (Bristol-Myers Squibb)^b	q1w	1 ml	Prefilled syringe, prefilled pen/autoinjector

TNF tumor necrosis factor, IL interleukin, qXw once every X weeks, qXd once every X days, qXm once every X months

^aOnly a subcutaneous formulation marketed

^bBoth subcutaneous and intravenous formulations marketed